Fabio Casciano
Paolo D. Pigatto2
Eva Reali- 1Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy
- 2Department of Dermatology and Venereology, I.R.C.C.S. Istituto Ortopedico Galeazzi, University of Milan, Milan, Italy
- 3Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy
- 4Laboratory of Translational Immunology, I.R.C.C.S. Istituto Ortopedico Galeazzi, Milan, Italy
The key role of T cells in the pathogenesis of cutaneous psoriasis has been well described in the last decade and the knowledge of the relative role of the different subsets of T cells in psoriasis pathogenesis has considerably evolved. Now, it is clear that IL-17A-producing T cells, including Th17/Tc17, have a central role in the pathogenesis of cutaneous psoriasis and therapies blocking the IL-17A pathway show high clinical efficacy. By contrast, the contribution of IFNγ-producing T cells has progressively become less clear because of the lack of efficacy of anti-IFNγ antibodies in clinical studies. In parallel, the role of CD8+ T cells specific for self-antigens has been revived and increasing evidence now indicates that in psoriatic skin the majority CD8+ T cells are present in the form of epidermal tissue-resident memory T cells. In the last years it also emerged the possibility of a contribution of T cell recirculation in the pathogenesis of psoriasis and its systemic manifestations. The aim of this review is to define a hierarchy for the different subsets of T cells in the T cell-mediated inflammatory cascade in psoriatic skin. This analysis will possibly help to distinguish the subsets that initiate the disease, those involved in the establishment of the self-sustaining amplification loop that leads to the cutaneous clinical manifestations and finally the subsets that act as downstream players in established lesions. Specific T cell subpopulations finally will be considered for their possible role in propagating inflammation at distant sites and for representing a link with systemic inflammation and cardiovascular comorbidities.
Introduction
Psoriasis is a chronically relapsing inflammatory disease of the skin affecting about 2% of the population worldwide.
Histologically, psoriasis is characterized by three principal features: epidermal hyperplasia, leukocyte infiltrate, and an increased number of tortuous and leaky vessels in the dermis (1–3). In recent studies, the presence of lymphoid aggregates/memory T cell clusters in the dermis of psoriatic plaques has been reported (4, 5).
20–30% of patients with psoriasis also develops psoriatic arthritis (PsA) and there is evidence that psoriasis is associated with systemic inflammation and with comorbidities, such as cardiovascular disease (6–12).
With regards to the pathogenesis, it is now emerging that psoriasis is an immune-mediated disease with a central autoimmune component mediated by T cells. Specifically, the disease pathogenesis involves a dynamic interplay between dermal dendritic cells, T cells (CD8+ autoreactive T cells, Th1, and Th17) and keratinocytes giving rise to a self-sustaining inflammatory cycle that develops around the TNF/IL-23/IL-17A axis (13–17). Despite this evidence, the hierarchical sequence of T cell-mediated events in the psoriatic inflammatory cascade is not completely defined. On the basis of the current literature and results of cytokine-blocking therapies it is possible to distinguish, in the T cell-mediated psoriatic inflammatory cascade, (i) an initial skin T cell activation phase, (ii) the establishment of chronic inflammation, (iii) the maintenance of clinically established lesions, and (iv) the egress from the skin of specific subsets of T cells that could possibly take part in the development of extra-cutaneous manifestations of psoriasis, including joint inflammation and cardiovascular comorbidities (18, 19).
T Cell Hierarchy in the Formation of Psoriatic Plaques
T cell responses against self-antigens in psoriasis are initiated by dendritic cells in the dermis of pre-psoriatic skin (20). Mature dermal dendritic cells can produce TNFα and IL-23, present self-antigens, and stimulate the activation of autoreactive CD8+ T cells together with a fraction of CD4+ T cells polarized toward Th17 phenotype or the IL-17+IFNγ+ pathogenic Th1/Th17 as described by Annunziato and co-workers and Eisdmo and co-workers (20–23).
Activated T cells can migrate to the epidermis and recognize epidermal autoantigens and possibly progress toward differentiation to tissue-resident memory T cells (TRM) characterized by CD69+CD103+CCR7−CD45RA−CD62L− phenotype (24, 25). Recognition of epidermal autoantigens by Tc1/Tc17 induces the secretion of cytokines, including IL-22, that mediate the initial phase of epidermal hyperproliferation and activation of keratinocytes (Figure 1A). These will produce chemokines and antimicrobial peptides, which lead to the progression of the inflammatory process (26–29).
Figure 1. T cell-mediated events in the psoriatic inflammatory cascade. (A) Activation of autoreactive T cells by self-antigens presented in the dermal lymphoid aggregates. Establishment of CD8+ TRM cells as central autoimmune component of disease pathogenesis and potential mechanisms of site-specific disease memory. (B) Polyclonal T cells proliferation and Th17/Tc17-mediated inflammation around the IL-23/IL-17A axis. (C) Recruitment of Th1/Tc1 cells, with multiple specificities, from the blood stream, induced by CXCL10 chemokines. Recirculation of T cells from the skin to the blood can spread inflammation at systemic level and at distant sites.
Epidermal autoantigens include LL-37 antimicrobial peptide expressed by keratinocytes, keratin 17, and melanocyte-derived antigen ADAMTS-like protein 5 (ADAMTSL5) recognized by IL-17A-producing CD8+ T cells, restricted by HLA-C*06:02 (26, 30–35).
This evidence together with early studies strongly supports that CD8+ T cells represent the autoimmune core of the disease. In psoriatic skin lesions, CD8+ T cells accumulate in the form of TRM with a pathogenic IFNγ–IL-17A cytokine profile that were detected also in resolved psoriatic lesions and identified as potential mechanisms of site-specific disease memory (20, 25, 36–42).
The major role of CD8+ T cells is also strongly supported by the fact that the main psoriasis risk gene is the HLA-class I allele HLA-C*06:02 on psoriasis susceptibility locus 1 on chomosome 6 and additional HLA-class I alleles are associated with psoriasis (43, 44).
Among tissue-resident T cells in human psoriatic skin, Clark and co-workers have recently shown that the vast majority has an αβ TCR (42), despite γδ T cells have been reported to play a role in the production of IL-17A and maintenance of inflammation (45, 46).
As regards to the TCR repertoire, studies of TCRBV chain sequencing showed mono or oligoclonal expansions of T cells mainly of CD8+ lineage in psoriatic skin (47–49). TCRBV expansion indicates antigen-driven CD8+ T cell responses, whereas the CD4+ T cell fraction was reported to be polyclonal (50). In patients with cutaneous psoriasis, however, the presence of oligoclonal TCRBV expansion in peripheral blood is debated (51, 52). Two different studies of high-throughput sequencing of the entire TCR repertoire have shown that alongside with a limited oligoclonally expanded T cell subpopulation in psoriatic skin that was in part retained in resolved lesions, there was a vast majority of polyclonal T cells (42, 53). This data suggests that similarly to what has been described in PsA by Winchester and co-workers, antigen-driven mono and oligoclonally expanded T cell populations represent a limited component of the T cell reactions in psoriatic skin, whereas the vast majority is represented by polyclonal CD4+ T cells that are not present in resolved lesions (54).
This evidence together confers to autoreactive CD8+ T cells a dominant role in the plaque formation and in psoriasis recurrence and possibly a common role in psoriasis and PsA. It also underlines the importance of mechanisms of T cell plasticity and polarization toward pathogenic phenotypes.
With respect to CD8 T cell targetability, a recent study on a AGR mouse model of psoriasis has reported the accumulation of epidermal CD8+ T cells during psoriasis development which was associated with IL-17A production and increased keratinocyte proliferation. Importantly, in this study injection of anti-CD8 antibody completely prevented psoriasis development (29).
Nevertheless, it is likely that Tc1/Tc17 autoreactive CD8+ TRM cells overlap their features and functions with the cells that under physiological conditions work as immune sentinels at barrier tissue. For this reason in a clinical setting, it could be difficult to target epidermal CD8+ TRM cells by the available immunotherapeutic tools without incurring in major adverse effects (20, 28, 29, 37).
As regards T helper cells, they have been reported to be more abundant in psoriatic skin lesions. While initially they were described mainly as Th1 cells, more recently the attention has been focused on IL-17-producing cells and the IL-23/Th17 axis clearly emerged as central in the control of the pro-inflammatory cycle in psoriatic plaques (14, 15). The high efficacy and fast outcome of IL-17A blocking therapies in resolving cutaneous clinical symptoms has strongly supported this concept (28, 55, 56). In addition, at skin level an expanded subset of T cells that produces IL-22 but not IL-17A (Th22) with a main role in the induction of acanthosis was identified. Importantly, these cells were found to be present also in resolved psoriatic lesions (57, 58).
In line with the key role of IL-17A, the main gene variants associated with psoriasis outside the MHC locus are single nucleotide polymorphisms, belonging to the IL-23/IL-17A axis (IL23R, IL12B, and IL23A) and the NF-κB pathway (TNFAIP3) (44, 59). It is, however, possible to hypothesize that Th17 or pathogenic Th1/Th17 cells could be expanded in the dermis as an event downstream of the epidermal autoimmune TRM and occurs through bystander activation mechanisms like the one described by Winchester and co-workers in psoriatic synovial tissues (54).
In this view, the cycle that develops around the IL-23/IL-17A axis could involve some antigen-driven populations and a considerable fraction of polyclonally expanded T cells that can represent the second step of the pro-inflammatory cascade, responsible for the amplification of inflammation and for the exacerbation of clinical symptoms (Figure 1B).
As a consequence of the strong evidence of the central role of IL-17A-producing cells, the relevance of Th1 cells and IFNγ has become less clear. In lesional skin of psoriasis patients, Th1 cells and IFNγ levels are clearly increased (60, 61). However, in a small pilot study in patients with psoriasis, treatment with a humanized anti-IFNγ antibody induced improvement of histological and some clinical parameters but only minor therapeutic effects (62).
These controversial findings focus on the complexity of the interplay between the Th1/Tc1 and Th17/Tc17 cells in the pathogenesis of psoriasis and it is not clear how the marked increase of IFNγ and IFNγ-producing cells in psoriatic skin can actually link with the failure of IFNγ-blockade to show therapeutic efficacy.
Results from a study by Kryczek et al. have suggested that IFNγ exerts one of its effects by programming myeloid dendritic cells to produce CCL20, ligand of CCR6, and to secrete IL-23. This in turn would favor the recruitment and expansion of IL-17A-producing cells (63, 64). On the other hand, IFNγ mRNA is markedly upregulated in psoriatic plaques and noticeably IFNγ-induced genes, such as CXCL9, CXCL10, and CXCL11 are strongly increased in psoriatic lesions (65).
In line with this evidence, we have previously reported gene expression data in psoriatic skin showing significant enhancement of CXCR3 and CXCL10 expression with an inverse correlation between the circulating fraction of CXCR3+ CD4+ effector memory T cells and the severity of cutaneous psoriasis (66, 67). Therefore, we can postulate an ultimate downstream phase in the psoriatic cascade, driven by the CXCL10/CXCR3 axis which induces the recruitment of Th1/Tc1 from the blood stream (Figure 1C).
T Cells in the Pathogenesis of PsA
Psoriatic arthritis develops in a fraction of patients with psoriasis and in the majority of cases it follows the development of the cutaneous disease by a mean of 10 years (68).
In addition to the skin, PsA targets the attachment sites of ligament to bone (entheses), the peripheral joints, and the spine (12, 69).
Enthesitis is indeed a distinctive feature of PsA and it has been hypothesized that, in PsA joints, inflammation can start from the entheses. The disease progression, in patients with PsA, can finally lead to destructive bone loss and 67% of patients exhibit signs of erosive bone disease (70).
Similarly to psoriasis, T cells are involved in the pathogenesis of PsA and reduction of CD3+ cells in PsA synovium correlated with the clinical response to biological therapies (71).
In PsA patients, Canete and co-workers have evidenced the presence of lymphoid aggregates in synovial tissues that was significantly reduced by TNF-blocking agents. This result could be paralleled by the observation of lymphoid aggregates in psoriatic skin and the role of CCR7/CCL19 axis, modulated by TNF in the initial clustering of dendritic cells and T cells in the dermis (4, 5, 72–75).
In line with the concept of shared pathogenic mechanisms between psoriasis and PsA, Belasco and colleagues provided the evidence that gene expression in PsA synovium was more closely related to gene expression in the PsA patient skin than to gene expression in the synovium of patients with other forms of arthritis. IL17 gene, however, was upregulated more in skin than in the synovium, whereas TNF and IFNγ were similarly upregulated in both tissues (76).
As regards the TCR repertoire analysis in PsA joints, Tassiulas et al. (47) showed oligoclonal and monoclonal T cell expansions in the synovial tissue, some of which were shared with the skin. In a subsequent study, Curran et al. performed TCR β-chain nucleotide sequencing in peripheral blood and synovial tissues/fluid showing that 76% of the clones in inflamed tissues were polyclonal, whereas 12% of the expanded clones had structurally homologous CDR3 β-chain sequence and were only CD8+ in lineage (54). Interestingly, some of the expanded CD8+ clones identified in the synovial tissue were present also in peripheral blood and joint fluid.
A second population of moderately expanded inflammation-related clones, that were either of CD4+ or CD8+ lineage, was identified only in inflamed synovial tissue and joint fluid. These cells could represent a secondary consequence of the inflammation induced by other proliferating clones.
Finally, one major population consisted of unexpanded polyclonal CD4+ T cells that did not persist in the tissue during methotrexate treatment, were most likely effector memory CD4+ T cells recruited by inflammatory chemokines released by other cell populations. The lack of clonal expansion in CD4+ T cells suggests a lower hierarchical role in driving inflammation.
These findings together suggest a role for cognate T cell responses in the pathogenesis of PsA and further suggest that T cell clones specific for identical or homologous antigens in skin and synovium may represent central elements in promoting inflammation in both tissues (47).
It remains to be established how self-reactive T cell responses in the skin, can be mechanistically linked to the one found in the synovial fluid and how these events can occur with years of time-lapse.
To this end, genetic association studies can provide some interpretation keys. In addition to the HLA-C*06:02 which is common with psoriatic plaque, additional HLA-alleles are associated with PsA. These HLA-alleles include B*08:01:01, B*27:05:02, B*38:01:01, and B*39:01:01 (77).
This underlines the importance of CD8+ T cells recognizing HLA-class I associated self-antigens in the pathogenesis of PsA and suggests that the autoimmune basis of PsA may be even broader than the one of cutaneous psoriasis. In this view, enthesis that anatomically links mechanical stress to immunologically active tissue (synovium), could be central for the pathogenesis (78).
Entheses are commonly subject to microdamage associated with local cytokine release, which may evolve into subsequent inflammation (79, 80). Inflammation in turn can favor cross-presentation of self-antigens.
It is, therefore, possible that recirculation of pathogenic skin T cells recognizing common self-antigens can start subclinical inflammation by localizing to the synovioenthesial complex (Figure 1C).
Patients with psoriatic disease have shown an increased level of circulating CCR6+ CD4+ TEM and TEFF cells that correlated positively with systemic inflammation (66). Therefore, it is possible to hypothesize that a fraction of IL-17-producing T cells recirculates from the skin and relocalize to the entheses.
This is reinforced by the findings of Sherlock et al. reporting that IL-17A+ cells locate mainly at the entheses and synovial tissues and by the evidence that among the genetic risk factors outside the MHC locus there are gene variants falling into the IL-23/IL-17A axis (77, 80–85). Importantly, it has been reported that IL-23 is expressed in synovial membrane with ectopic lymphoid tissue (78).
The fraction of IL-17A-producing cells recirculating from the skin could, therefore, determines subclinical inflammation and favor, in the long-term, cross-presentation of self-antigens and epitope spreading phenomena (73, 78).
In established PsA, it has also been reported an increased percentage of IL-17A-producing CD8+ T cells in synovial fluid which correlate with bone erosion and disease severity (86–88).
In the light of a hierarchical T cell clonality in psoriatic tissue and the evidence of the multiple-specific clones, including EBV-specific clones, observed in synovial fluid, we can postulate that massive recruitment of T cells with Th1/Tc1 phenotype from peripheral blood occurs as a consequences of inflammatory chemokine release (54). By analogy with the observation in psoriatic skin and by evidence from the data provided by Gladman and co-workers it is possible that CXCL10/CXCR3 axis can act as a downstream cell recruitment mechanism of tissue inflammation common to cutaneous psoriasis and PsA (89–91).
T Cells in Psoriasis-Associated Cardiovascular Comorbidities
Increasing epidemiological and clinical evidence indicates that psoriasis is an independent risk factor for cardiovascular disease (92, 93).
As a consequence of poorly controlled tissue inflammation, psoriasis patients can develop systemic inflammation and atherosclerosis. In this process, it has been postulated that inflamed tissue-derived factors or cells may directly affect distant vessels for the development of athero-thrombosis (7, 94, 95). Nevertheless, the cellular mechanisms that link the cutaneous manifestations of plaque psoriasis with the initiation and progression of atherosclerosis in psoriasis patients are largely unknown.
A recent study on human tissues showed that psoriasis and atherosclerosis exhibit significant overlap of their transcriptomes and in particular that TNF, IFNg, and IFNγ-induced genes, which are common between psoriasis and atherosclerosis may provide the link between the two diseases (96). By contrast, IL-17A and CCL20 were higher in psoriasis than in atherosclerotic tissue, whereas IL17R gene was expressed at similar levels.
Because of the link between IL-17A and neutrophil infiltration in atherosclerotic plaques and its key role in the pathogenesis of psoriasis it has been suggested that the IL-17A/neutrophil axis could take part to atherogenesis associated with psoriatic disease (97). Nevertheless, the role of IL-17A in psoriasis-associated atherosclerosis is still controversial. Indeed, Usui et al. reported that IL-17A deficiency protected against atherosclerosis in apoE−/− mice due to reduced macrophage infiltration and inflammatory cytokine secretion in the lesions (98).
Other mouse studies have indicated that IL-17A may promote plaque stability by contributing to fibrous cap formation (99). Collectively, the results indicate that IL-17A may exert both anti- and pro-atherogenic effects, depending on the inflammatory context. However, further studies will be necessary to clarify the contribution of T cells recirculating from the psoriatic plaque in the development of atherosclerosis.
Implications for the Development of Therapeutic Protocols
From this analysis it emerges a differential contribution of the individual subsets of T cells in the pathogenesis of psoriasis, PsA, and associated cardiovascular comorbidities namely, atherosclerosis. In particular, TNFα has a relevant role in inducing the CCL19/CCR7-mediated formation of clusters of dendritic cells and T cells in both psoriasis and PsA. It also emphasizes the role of IL-23/IL-17 axis in the amplification loop critical for the clinical manifestations of cutaneous psoriasis and possibly in the initial phase of join inflammation.
On the other hand, the possibility of a third step of CXCL10/CXCR3-mediated recruitment of Th1/Tc1 cells from the blood stream may explain the apparent controversy between the high amount of IFNγ-producing cells and the low therapeutic efficacy of anti-IFNγ antibody treatment.
Conclusion
By defining the hierarchy of the T cell-mediated events of the psoriatic cascade in psoriatic plaques it is possible to distinguish a core antigen-driven oligo or monoclonally expanded autoreactive CD8+ T cell component, a secondary self-reactive CD4+ T cell component, a polyclonal CD4+ Th17 and pathogenic Th1/Th17 population amplified by the IL-23/IL-17A axis, and a downstream recruitment of CXCR3+ T cells with different specificities induced by the upregulation of CXCL10 chemokine. Similarly in PsA the analysis of the TCR repertoire has evidenced central antigen-driven expansion of mainly CD8+ T cells and broad polyclonal CD4+ T cells expansion. In addition, a group of common clones were also expanded in peripheral blood of patients with PsA and T cell clones specific for identical or homologous antigens were present in both skin and in synovial tissues. These may represent central elements in promoting inflammation in both tissues. In addition, oligoclonally expanded clones in peripheral blood of patients with PsA may also suggest that T cell recirculation can represent a mechanistic link between skin and joints inflammation.
Author Contributions
FC wrote parts of the manuscript and prepared the figures. PP collaborated to the writing. PS and RG discussed the content and critically revised the manuscript. ER supervised the work and wrote the final version of the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding
The Psoriasis Research Program at the University of Ferrara receives support from Fondazione Natalino Corazza Onlus Psoriasis & Co., Bologna, Italy.
References
1. Boehncke WH, Brembilla NC. Unmet needs in the field of psoriasis: pathogenesis and treatment. Clin Rev Allergy Immunol (2017). doi:10.1007/s12016-017-8634-3
2. Boehncke WH, Schon MP. Psoriasis. Lancet (2015) 386(9997):983–94. doi:10.1016/S0140-6736(14)61909-7
3. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev (2014) 13(4–5):490–5. doi:10.1016/j.autrev.2014.01.008
4. Mitsui H, Suarez-Farinas M, Belkin DA, Levenkova N, Fuentes-Duculan J, Coats I, et al. Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. J Invest Dermatol (2012) 132(6):1615–26. doi:10.1038/jid.2012.33
5. Bose F, Petti L, Diani M, Moscheni C, Molteni S, Altomare A, et al. Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis. Am J Pathol (2013) 183(2):413–21. doi:10.1016/j.ajpath.2013.04.021
6. Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 62(2):195–201. doi:10.1016/j.cyto.2013.03.013
7. Boehncke WH, Gladman DD, Chandran V. Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. J Rheumatol (2011) 38(3):567–71. doi:10.3899/jrheum.101124
8. Siegel D, Devaraj S, Mitra A, Raychaudhuri SP, Raychaudhuri SK, Jialal I. Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol (2013) 44(2):194–204. doi:10.1007/s12016-012-8308-0
9. Boehncke WH, Kirby B, Fitzgerald O, van de Kerkhof PC. New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease. J Eur Acad Dermatol Venereol (2014) 28(3):264–70. doi:10.1111/jdv.12222
10. Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol (2013) 14(5):377–88. doi:10.1007/s40257-013-0032-x
11. Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin Arthritis Rheum (2016) 46(3):291–304. doi:10.1016/j.semarthrit.2016.05.012
12. Wittkowski KM, Leonardi C, Gottlieb A, Menter A, Krueger GG, Tebbey PW, et al. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One (2011) 6(6):e20279. doi:10.1371/journal.pone.0020279
13. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 129(6):1339–50. doi:10.1038/jid.2009.59
14. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol (2013) 34(4):174–81. doi:10.1016/j.it.2012.11.005
15. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol (2014) 14(9):585–600. doi:10.1038/nri3707
16. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs (2013) 22(8):993–1005. doi:10.1517/13543784.2013.806483
17. Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol (2017) 31(10):1616–26. doi:10.1111/jdv.14433
18. Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev (2015) 14(4):286–92. doi:10.1016/j.autrev.2014.11.012
19. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol (2014) 32:227–55. doi:10.1146/annurev-immunol-032713-120225
20. Gallais Serezal I, Classon C, Cheuk S, Barrientos-Somarribas M, Wadman E, Martini E, et al. Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome. J Invest Dermatol (2018). doi:10.1016/j.jid.2018.02.030
21. Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 and non-classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. Int Arch Allergy Immunol (2014) 164(3):171–7. doi:10.1159/000363502
22. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol (2009) 129(1):79–88. doi:10.1038/jid.2008.194
23. Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol (2009) 129(2):302–8. doi:10.1038/jid.2008.225
24. Mackay LK, Kallies A. Transcriptional regulation of tissue-resident lymphocytes. Trends Immunol (2017) 38(2):94–103. doi:10.1016/j.it.2016.11.004
25. Cheuk S, Wiken M, Blomqvist L, Nylen S, Talme T, Stahle M, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol (2014) 192(7):3111–20. doi:10.4049/jimmunol.1302313
26. Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun (2014) 5:5621. doi:10.1038/ncomms6621
27. Lande R, Chamilos G, Ganguly D, Demaria O, Frasca L, Durr S, et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur J Immunol (2014) 45(1):203–13. doi:10.1002/eji.201344277
28. Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol (2018) 54(1):102–13. doi:10.1007/s12016-018-8668-1
29. Di Meglio P, Villanova F, Navarini AA, Mylonas A, Tosi I, Nestle FO, et al. Targeting CD8(+) T cells prevents psoriasis development. J Allergy Clin Immunol (2016) 138(1):274–6.e6. doi:10.1016/j.jaci.2015.10.046
30. Arakawa A, Siewert K, Stohr J, Besgen P, Kim SM, Ruhl G, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med (2015) 212(13):2203–12. doi:10.1084/jem.20151093
31. Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B, Good MF, Valdimarsson H, Jonsdottir I. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol (1999) 117(3):580–6. doi:10.1046/j.1365-2249.1999.01013.x
32. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol (2004) 138(1):83–93. doi:10.1111/j.1365-2249.2004.00600.x
33. McFadden J, Valdimarsson H, Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. Br J Dermatol (1991) 125(5):443–7. doi:10.1111/j.1365-2133.1991.tb14769.x
34. Valdimarsson H, Sigmundsdottir H, Jonsdottir I. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clin Exp Immunol (1997) 107(Suppl 1):21–4.
35. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, Gudjonsson JE, Johnston A. Psoriasis – as an autoimmune disease caused by molecular mimicry. Trends Immunol (2009) 30(10):494–501. doi:10.1016/j.it.2009.07.008
36. Cheuk S, Schlums H, Gallais Serezal I, Martini E, Chiang SC, Marquardt N, et al. CD49a expression defines tissue-resident CD8(+) T cells poised for cytotoxic function in human skin. Immunity (2017) 46(2):287–300. doi:10.1016/j.immuni.2017.01.009
37. Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol (2007) 28(2):51–7. doi:10.1016/j.it.2006.12.005
38. Conrad C, Boyman O, Tonel G, Tun-Kyi A, Laggner U, de Fougerolles A, et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med (2007) 13(7):836–42. doi:10.1038/nm1605
39. Hijnen D, Knol EF, Gent YY, Giovannone B, Beijn SJ, Kupper TS, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. J Invest Dermatol (2013) 133(4):973–9. doi:10.1038/jid.2012.456
40. Ortega C, Fernandez AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol (2009) 86(2):435–43. doi:10.1189/JLB.0109046
41. Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 5(11):e14108. doi:10.1371/journal.pone.0014108
42. Matos TR, O’Malley JT, Lowry EL, Hamm D, Kirsch IR, Robins HS, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing alphabeta T cell clones. J Clin Invest (2017) 127(11):4031–41. doi:10.1172/JCI93396
43. Gudjonsson JE, Karason A, Antonsdottir A, Runarsdottir EH, Hauksson VB, Upmanyu R, et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol (2003) 148(2):233–5. doi:10.1046/j.1365-2133.2003.05115.x
44. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun (2015) 64:66–73. doi:10.1016/j.jaut.2015.07.008
45. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity (2011) 35(4):596–610. doi:10.1016/j.immuni.2011.08.001
46. Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, Ali N, et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. J Immunol (2011) 187(5):2783–93. doi:10.4049/jimmunol.1100804
47. Tassiulas I, Duncan SR, Centola M, Theofilopoulos AN, Boumpas DT. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol (1999) 60(6):479–91. doi:10.1016/S0198-8859(99)00034-8
48. Lin WJ, Norris DA, Achziger M, Kotzin BL, Tomkinson B. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol (2001) 117(6):1546–53. doi:10.1046/j.0022-202x.2001.01548.x
49. Bour H, Puisieux I, Even J, Kourilsky P, Favrot M, Musette P, et al. T-cell repertoire analysis in chronic plaque psoriasis suggests an antigen-specific immune response. Hum Immunol (1999) 60(8):665–76. doi:10.1016/S0198-8859(99)00027-0
50. Norris DA, Travers JB, Leung DY. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol (1997) 109(1):1–4. doi:10.1111/1523-1747.ep12276285
51. Cao X, Wa Q, Wang Q, Li L, Liu X, An L, et al. High throughput sequencing reveals the diversity of TRB-CDR3 repertoire in patients with psoriasis vulgaris. Int Immunopharmacol (2016) 40:487–91. doi:10.1016/j.intimp.2016.10.004
52. Borgato L, Puccetti A, Beri R, Codella O, Frigo A, Simeoni S, et al. The T cell receptor repertoire in psoriatic synovitis is restricted and T lymphocytes expressing the same TCR are present in joint and skin lesions. J Rheumatol (2002) 29(9):1914–9.
53. Harden JL, Hamm D, Gulati N, Lowes MA, Krueger JG. Deep sequencing of the T-cell receptor repertoire demonstrates polyclonal T-cell infiltrates in psoriasis. F1000Res (2015) 4:460. doi:10.12688/f1000research.6756.1
54. Curran SA, FitzGerald OM, Costello PJ, Selby JM, Kane DJ, Bresnihan B, et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol (2004) 172(3):1935–44.
55. Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nat Med (2015) 21(7):730–8. doi:10.1038/nm.3897
56. Canavan TN, Elmets CA, Cantrell WL, Evans JM, Elewski BE. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol (2016) 17(1):33–47. doi:10.1007/s40257-015-0162-4
57. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 119(12):3573–85. doi:10.1172/JCI40202
58. Diani M, Altomare G, Reali E. T helper cell subsets in clinical manifestations of psoriasis. J Immunol Res (2016) 2016:7692024. doi:10.1155/2016/7692024
59. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet (2007) 80(2):273–90. doi:10.1086/511051
60. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol (1993) 101(5):701–5. doi:10.1111/1523-1747.ep12371679
61. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol (2009) 124(5):1022–10.e1–395. doi:10.1016/j.jaci.2009.08.046
62. Harden JL, Johnson-Huang LM, Chamian MF, Lee E, Pearce T, Leonardi CL, et al. Humanized anti-IFN-gamma (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol (2015) 135(2):553–6. doi:10.1016/j.jaci.2014.05.046
63. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol (2008) 181(7):4733–41. doi:10.4049/jimmunol.181.7.4733
64. Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, et al. Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol (2008) 181(9):5842–6. doi:10.4049/jimmunol.181.9.5842
65. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol (2005) 175(4):2721–9. doi:10.4049/jimmunol.175.4.2721
66. Diani M, Galasso M, Cozzi C, Sgambelluri F, Altomare A, Cigni C, et al. Blood to skin recirculation of CD4+ memory T cells associates with cutaneous and systemic manifestations of psoriatic disease. Clin Immunol (2017) 180:84–94. doi:10.1016/j.clim.2017.04.001
67. Sgambelluri F, Diani M, Altomare A, Frigerio E, Drago L, Granucci F, et al. A role for CCR5(+)CD4 T cells in cutaneous psoriasis and for CD103(+) CCR4(+) CD8 Teff cells in the associated systemic inflammation. J Autoimmun (2016) 70:80–90. doi:10.1016/j.jaut.2016.03.019
68. Dhir V, Aggarwal A. Psoriatic arthritis: a critical review. Clin Rev Allergy Immunol (2013) 44(2):141–8. doi:10.1007/s12016-012-8302-6
69. Anandarajah AP, Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol (2004) 16(4):338–43.
70. van Kuijk AW, Tak PP. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep (2011) 13(4):353–9. doi:10.1007/s11926-011-0181-y
71. Pontifex EK, Gerlag DM, Gogarty M, Vinkenoog M, Gibbs A, Burgman I, et al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy – a single centre, open-label study. Arthritis Res Ther (2011) 13(1):R7. doi:10.1186/ar3228
72. Kim TG, Jee H, Fuentes-Duculan J, Wu WH, Byamba D, Kim DS, et al. Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis. J Invest Dermatol (2014) 134(5):1462–5. doi:10.1038/jid.2013.534
73. Canete JD, Santiago B, Cantaert T, Sanmarti R, Palacin A, Celis R, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis (2007) 66(6):720–6. doi:10.1136/ard.2006.062042
74. Celis R, Planell N, Fernandez-Sueiro JL, Sanmarti R, Ramirez J, Gonzalez-Alvaro I, et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther (2012) 14(2):R93. doi:10.1186/ar3817
75. Chimenti MS, Triggianese P, Nuccetelli M, Terracciano C, Crisanti A, Guarino MD, et al. Auto-reactions, autoimmunity and psoriatic arthritis. Autoimmun Rev (2015) 14(12):1142–6. doi:10.1016/j.autrev.2015.08.003
76. Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol (2015) 67(4):934–44. doi:10.1002/art.38995
77. Winchester R, Giles J, Jadon D, Haroon M, McHugh N, FitzGerald O. Implications of the diversity of class I HLA associations in psoriatic arthritis. Clin Immunol (2016) 172:29–33. doi:10.1016/j.clim.2016.07.019
78. Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med (2012) 18(7):1018–9. doi:10.1038/nm.2854
79. Novelli L, Chimenti MS, Chiricozzi A, Perricone R. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev (2014) 13(1):64–9. doi:10.1016/j.autrev.2013.08.006
80. Sherlock JP, Buckley CD, Cua DJ. The critical role of interleukin-23 in spondyloarthropathy. Mol Immunol (2014) 57(1):38–43. doi:10.1016/j.molimm.2013.06.010
81. Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther (2013) 15(5):R136. doi:10.1186/ar4317
82. Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev (2014) 13(4–5):496–502. doi:10.1016/j.autrev.2014.01.050
83. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med (2012) 18(7):1069–76. doi:10.1038/nm.2817
84. Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol (2009) 5(2):83–91. doi:10.1038/ncprheum0987
85. Apel M, Uebe S, Bowes J, Giardina E, Korendowych E, Juneblad K, et al. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum (2013) 65(5):1224–31. doi:10.1002/art.37885
86. Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol (2014) 66(5):1272–81. doi:10.1002/art.38376
87. Adamopoulos IE, Bowman EP. Immune regulation of bone loss by Th17 cells. Arthritis Res Ther (2008) 10(5):225. doi:10.1186/ar2502
88. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther (2010) 12(1):R29. doi:10.1186/ar2936
89. Chandran V, Gladman DD. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep (2010) 12(4):288–94. doi:10.1007/s11926-010-0107-0
90. Muntyanu A, Abji F, Liang K, Pollock RA, Chandran V, Gladman DD. Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis. Arthritis Res Ther (2016) 18(1):296. doi:10.1186/s13075-016-1196-6
91. Abji F, Pollock RA, Liang K, Chandran V, Gladman DD. Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol (2016) 68(12):2911–6. doi:10.1002/art.39800
92. Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis (2015) 7(5):187–95. doi:10.1177/1759720X15591801
93. Eder L, Joshi AA, Dey AK, Cook R, Siegel EL, Gladman DD, et al. TNF-alpha inhibitors are associated with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol (2017) 70(3):408–16. doi:10.1002/art.40366
94. Wang Y, Gao H, Loyd CM, Fu W, Diaconu D, Liu S, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol (2012) 132(8):2067–75. doi:10.1038/jid.2012.112
95. Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol (2018) 70(3):396–407. doi:10.1002/art.40389
96. Mehta NN, Teague HL, Swindell WR, Baumer Y, Ward NL, Xing X, et al. IFN-gamma and TNF-alpha synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep (2017) 7(1):13831. doi:10.1038/s41598-017-14365-1
97. Sanda GE, Belur AD, Teague HL, Mehta NN. Emerging associations between neutrophils, atherosclerosis, and psoriasis. Curr Atheroscler Rep (2017) 19(12):53. doi:10.1007/s11883-017-0692-8
98. Usui F, Kimura H, Ohshiro T, Tatsumi K, Kawashima A, Nishiyama A, et al. Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. Biochem Biophys Res Commun (2012) 420(1):72–7. doi:10.1016/j.bbrc.2012.02.117
Keywords: psoriasis, skin, inflammation, psoriatic arthritis, TCR repertoire, comorbidities
Citation: Casciano F, Pigatto PD, Secchiero P, Gambari R and Reali E (2018) T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities. Front. Immunol. 9:1390. doi: 10.3389/fimmu.2018.01390
Received: 27 April 2018; Accepted: 05 June 2018;
Published: 19 June 2018
Edited by:
Massimo Gadina, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), United StatesReviewed by:
Katia Boniface, Université de Bordeaux, FranceKamran Ghoreschi, Universität Tübingen, Germany
Copyright: © 2018 Casciano, Pigatto, Secchiero, Gambari and Reali. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eva Reali, eva.reali@unife.it, eva.reali@grupposandonato.it